Finance

Lists
SLN:NASDAQ
Silence Therapeutics PLC - ADR
19,73 $
+0,05%
(+0,010) 1D
19,78 $
+0,28% (+0,055)
After hours
Closed: 6 նոյ, 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SLN...
Open
19,75 $
High
19,77 $
Low
19,72 $
Mkt. cap
1,22 մլրդ
Avg. vol.
4,28 մլն
Volume
958,44 հզր
52-wk high
19,86 $
52-wk low
4,19 $
EPS
-1,45 $
Beta
1,34
Shares outstanding
60,21 մլն
No. of employees
88
Open
19,75 $
High
19,77 $
Low
19,72 $
Mkt. cap
1,22 մլրդ
Avg. vol.
4,28 մլն
Volume
958,44 հզր
52-wk high
19,86 $
52-wk low
4,19 $
EPS
-1,45 $
Beta
1,34
Shares outstanding
60,21 մլն
No. of employees
88
News stories
From web sources and news partners
Profile
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London. Wikipedia
About Silence Therapeutics PLC - ADR
CEOCraig A Tooman
Employees88
Founded1994
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 5 analysts giving stock ratings to SLN in the past 3 months
Hold
Buy
1
Hold
4
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for SLN in the last 3 months.
Highest
Current 19,73 $
32,00 $ (+62,19%)
Average
23,00 $ (+16,57%)
Lowest
20,00 $ (+1,37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Hold
Downgraded
20,00 $
+1,4%
10/21/2026
Andrew Tsai
Jefferies
Hold
Downgraded
20,00 $
+1,4%
10/19/2026
Myles Minter
William Blair
Hold
Downgraded
-
-
10/19/2026
Keay Nakae
Chardan Capital
Hold
Downgraded
20,00 $
+1,4%
10/19/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
32,00 $
+62,2%
08/11/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
4,00 $
-79,7%
07/27/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Initiated
-
-
06/24/2026
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
159,00 հզր
34,00 հզր
422,00 հզր
-
Cost of goods sold
64,00 հզր
12,00 հզր
11,00 հզր
-
Cost of revenue
64,00 հզր
12,00 հզր
11,00 հզր
-
Research and development expenses
17,96 մլն
8,92 մլն
8,43 մլն
8,37 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,80 մլն
3,73 մլն
7,03 մլն
4,72 մլն
Operating expense
23,76 մլն
12,65 մլն
15,46 մլն
13,09 մլն
Total operating expenses
23,82 մլն
12,66 մլն
15,47 մլն
13,09 մլն
Operating income
-23,66 մլն
-12,63 մլն
-15,05 մլն
-13,09 մլն
Other non operating income
770,00 հզր
865,00 հզր
571,00 հզր
669,00 հզր
EBT including unusual items
-20,96 մլն
-11,77 մլն
-14,96 մլն
-12,27 մլն
EBT excluding unusual items
-20,96 մլն
-11,77 մլն
-14,96 մլն
-12,27 մլն
Income tax expense
1,00 հզր
-
-
1,00 հզր
Effective tax rate
-
-
-
-0,01%
Other operating expenses
-
-
-
-
Net income
-20,96 մլն
-11,77 մլն
-14,96 մլն
-12,27 մլն
Net profit margin
-13 181,13%
-34 617,65%
-3 544,31%
-
Earnings per share
-0,15
-0,27
-0,33
-0,27
Interest and investment income
-
15,00 հզր
-
-
Interest expense
-
-
-
-
Net interest expenses
-
15,00 հզր
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-23,50 մլն
-12,52 մլն
-14,94 մլն
-12,98 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps